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Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by
progressive weakness and muscle atrophy related to the loss of upper and lower motor 
neurons (MNs) without a curative treatment. There is experimental evidence suggesting 
that retinoids may be involved in ALS pathogenesis. Bexarotene (Bxt) is a retinoid-X
receptor agonist used in the treatment of cutaneous lymphoma with a favorable safety
profile whose effects have been recently investigated in other neurodegenerative diseases. 
In this study, we analyze the potential therapeutic effect of Bxt in the SOD1G93A mouse
model of ALS. Mice were treated with Bxt or vehicle five times per week from day 60
onward. Survival, weight, and neuromuscular function studies together with histological 
and biochemical analyses were performed. Bxt significantly delayed motor function
deterioration, ameliorated the loss of body weight, and extended mice survival up to
30% of the symptomatic period. Histological analyses of the lumbosacral spinal cord
revealed that Bxt markedly delayed the early motor-neuron degeneration occurring at
presymptomatic stages in ALS-transgenic mice. Bxt treatment contributed to preserve
the MN homeostasis in the SOD1G93A mice. Particularly, it reduced the neuronal loss and 
the chromatolytic response, induced nucleolar hypertrophy, decreased the formation of 
ubiquitylated inclusions, and modulated the lysosomal response. As an agonist of the
retinoic-X receptor (RXR) pathway, Bxt notably increased the nuclear expression of the
RXRα throughout transcriptionally active euchromatin domains. Bxt also contributed to
protect the MN environment by reducing reactive astrogliosis and preserving perisomatic 
synapsis. Overall, these neuroprotective effects suggest that treatment with Bxt could be 
useful in ALS, particularly in those cases related to SOD1 mutations.
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introduction
Amyotrophic lateral sclerosis (ALS) is the most common disease affecting the motor neurons (MNs) 
with an annual incidence that ranges from 2 to 4 cases per 100,000 people. It is characterized by 
progressive loss of upper and lower MNs, accompanied by neuromuscular junction denervation. Death 
occurs within 2–5 years after diagnosis, usually due to respiratory failure (Kunst, 2004). Although 
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several therapies have been tried, riluzole (a glutamate antagonist) 
is the only drug currently approved by the U.S. Food and Drug 
Administration (FDA) for ALS treatment. However, it has shown 
a very poor effect in patients’ survival (Cheah et al., 2010; Miller 
et al., 2012).
Approximately 90% of ALS cases are sporadic (sALS), whereas 
the remaining 10% have a hereditary origin and tend to cluster into 
families (fALS). Up to 20% of fALS cases are due to mutations of 
the gene encoding superoxide dismutase 1 (SOD1) (Pasinelli and 
Brown, 2006; Rothstein, 2009; Ferraiuolo et al., 2011). This is also 
the basis of a commonly used transgenic mouse model expressing 
the human SOD1 gene with the G93A mutation (Gurney et al., 
1994). High-copy SOD1G93A transgenic mice recapitulate much 
of the pathophysiology of human ALS, including progressive 
MN degeneration, functional impairment, and reduced lifespan 
(Gurney et al., 1994). Furthermore, a relationship between SOD1 
mutations and sALS has recently been reported supporting the 
translational value of studies using transgenic SOD1 mice (Bosco 
et al., 2010).
The mechanisms involved in ALS pathogenesis remain unclear 
and are thought to be multiple (Robberecht and Philips, 2013). 
Disturbances of RNA processing, oxidative and endoplasmic reticu-
lum (ER) stress, impaired protein degradation with protein aggrega-
tion, axonal transport defects, and glial cell dysfunction represent 
some of the mechanisms that have been related to ALS (Corona et al., 
2007; Schmidt et al., 2009; Lemmens et al., 2010; Andersen and Al 
Chalabi, 2011; Philips and Robberecht, 2011; Bendotti et al., 2012; 
Majounie et al., 2012; Hetz and Mollereau, 2014).
Biochemical analyses have also identified some pathways poten-
tially involved in ALS pathogenesis, including retinoid pathways. 
Thus, it has been reported that wild type mice fed with a retinoid-
free diet develop a clinical phenotype resembling ALS with loss of 
MNs in the anterior horn and forelimb paralysis (Corcoran et al., 
2002). Additionally, Kolarcik and Bowser (2012) have suggested 
that retinoid signaling is altered in ALS. These authors showed 
that the pre-treatment of primary MN-enriched cultures with ada-
palene, a retinoic acid receptor beta (RARβ) agonist, protects MNs 
from cell death induced by oxidative stress. Furthermore, some 
reports propose that retinoic acid (RA) could modulate both the 
ubiquitin proteasome system (UPS) and the autophagy-lysosome 
pathways helping to maintain intracellular proteostasis (Rajawat 
et al., 2010; Anguiano et al., 2013; Cheng et al., 2013). Overall, these 
studies suggest a potential beneficial effect of retinoid pathway 
activation on neuron survival in MN-related diseases.
Bexarotene (Bxt) is a highly selective retinoid-X receptor (RXR) 
agonist with a favorable safety profile. As occurs with most of 
retinoids, hypothirodism, liver toxicity, and cutaneous disorders 
are the most common adverse reactions observed with its use 
(Duvic et al., 2001a,b). Bxt has been approved by the FDA for the 
treatment of cutaneous T-cell lymphoma, and is currently used 
as a long-term therapy in the clinical practice requiring periodic 
blood test monitoring (Farol and Hymes, 2004). This drug has 
already been tested in some mice models of neurodegenerative 
diseases. Thus, it has been shown that Bxt reduces the amyloid load 
in an Alzheimer disease mouse model and consequently induced a 
marked amelioration in the cognitive, social, and olfactory deficits 
(Cramer et  al., 2012). However, other investigators have only 
partially reproduced these results (Fitz et al., 2013; Price et al., 2013; 
Veeraraghavalu et al., 2013). On the other hand, Bxt has also been 
tested in a mouse model of Parkinson’s disease exhibiting beneficial 
effects (McFarland et al., 2013). Therefore, based on the potential 
neuroprotective effects of retinoid pathway activation (Mey and 
Rombach, 1999; Schrage et al., 2006; Kolarcik and Bowser, 2012), 
we hypothesized that Bxt could be useful in ALS. We planned 
this study to investigate its effects on both motor function and 
MN degeneration and survival in the transgenic SOD1G93A mouse 
model of ALS. Furthermore, we analyzed some potential neuropro-
tective mechanisms of Bxt including (i) cellular structures involved 
in proteostasis, such as protein synthesis machinery, nucleolus, 
and lysosomes, (ii) nuclear expression of the transcription factor 
RXRα, and (iii) reactive astroglial MN environment.
Materials and Methods
animals and Drug
Transgenic mice (B6SJLTg [SOD1-G93A] 1Gur/J) were obtained 
from The Jackson Laboratory (Bar Harbor, ME, USA) and 
maintained at the Animal Service of the University of Cantabria. 
The colony was maintained by mating heterozygous transgenic 
males with B6SJLF1/J hybrid females. Real time quantitative 
PCR (rtqPCR) of DNA obtained from tail tissue was used for 
genotyping, with specific primers detecting human SOD1 and 
the housekeeping mouse gene ApoB. Primer sequences were 
SOD1:GGG AAG CTG TTG TCC CAA G and CAA GGG GAG 
GTA AAA GAG AGC; ApoB: TCA CCA GTC ATT TCT GCC 
TTT G and GGG AAG CTG TTG TCC CAA G. Transgenic mice 
and control littermates were housed under controlled temperature 
and humidity, with a 12-h-light/12-h-dark cycle and free access to 
water and food. From day 105 of life, both transgenic and control 
mice were fed with Nutragel® (Bio-serv Frenchtown, NJ, USA). 
The experimental protocol was approved by the Ethics Committee 
of the University of Cantabria following the Spanish legislation. 
Animals were equally distributed into the experimental groups 
taking into account littermate origin, sex, weight, neuromuscular 
score baseline values, and transgenic load.
Micronized Bxt (Targretin®, Eisai, Japan) was water dissolved 
(30 mg/ml) and administered to transgenic SOD1G93A mice 5 days/
week at a dose of 100 mg/kg/day by gastric gavage. Another group 
of mice were treated with vehicle (water) using the same protocol 
that Bxt-treated mice. The experimental groups included in the 
study are summarized in Table 1.
survival, Weight, and neuromuscular Tests
To investigate long-term effects of Bxt administration, 27 trans-
genic mice were divided into two groups. Fifteen (9 males, 6 
females) and 12 (7 males, 5 females) mice were treated with Bxt 
and vehicle, respectively. Additionally, 12 wild type mice were also 
divided into two groups and treated with Bxt or vehicle under the 
regimen previously described. Treatment begun on day 60 of life 
and continued until sacrifice. Animals were weighted three times 
per week beginning at day 60. After a 2-week training period, 
neuromuscular tests (Rotarod and hanging test) were recorded 
twice a week beginning at 9  weeks of age until the end of the 
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experiment. A cylinder spinning at a constant speed of 12 rpm 
was used for the Rotarod test (Mouse Rota-Rod 47600, Ugo Basile, 
Argentina). On the other hand, a semi-spheric grid of 20 cm in 
diameter was used for the hanging test. The best of two attempts, 
which were separated by 10 min rest, was recorded. Following 
current recommendations (Vargas et  al., 2013), animals were 
euthanized by the time they developed severe paralysis, when 
they were not able to straighten up after turning them on their 
back in the following 15 s.
histological analysis
To study histological changes, 2 groups of 16 transgenic mice each 
were treated with Bxt or vehicle from day 60 until day 95. Eight 
mice of each group were euthanized on days 75 and 95, respec-
tively, and their spinal cords were processed for light or electron 
microscopy. The results were compared with those obtained in 
age-matched wild type mice.
light and confocal Microscopy
After deep anesthesia with pentobarbital (50 mg/kg) mice were per-
fused with 3.7% paraformaldehyde in PBS (pH 7.4) for 15 min. The 
lumbosacral enlargement of the spinal cord (L2-S1) was dissected 
and post-fixed for 2 h. Spinal cord fragments were either dehydrated 
and embedded in diethylene glycol or processed for mechanical 
dissociation of MNs as previously reported (Pena et al., 2001).
For neuronal dissociation, small tissue fragments from the 
anterior horn were transferred to a drop of PBS on a siliconized 
slide. Then, a coverslip was applied on top of the slide and the tissue 
was squashed by percussion with a histologic needle in order to 
dissociate neuronal cell bodies. The preparation was then frozen in 
dry ice, and the coverslip removed using a razor blade. Using this 
procedure, most MNs remained adhered to the slide. Cell samples 
were processed in 96% ethanol at 4°C for 10 min, which increases 
the adhesion of cells to the slide, and rehydrated progressively in 
70% ethanol and PBS. These squash preparations were used for 
propidium iodide (PI), a fluorescent staining of nucleic acids, and 
immunofluorescence.
Anterior horn cross sections, 2 μm thick, were processed for con-
ventional hematoxylin–eosin staining, PI cytochemical staining, 
Table 1 | experimental design.
experimental 
group
n Treatment start date 
(days)
end date 
(days)
sUrViVal anD neUrOMUscUlar FUncTiOn
Group 1 SOD1 G93A 15 (9m; 6f) Bexarotene 60 Sacrifice
Group 2 SOD1 G93A 12 (7m; 5f) Vehicle 60 Sacrifice
Group 3 Wild type 6 (3m; 3f) Bexarotene 60 120
Group 4 Wild type 6 (3m; 3f) Vehicle 60 120
hisTOlOgical sTUDies
Group 5 SOD1 G93A 16 (10m; 6f) Bexarotene 60 75/95
Group 6 SOD1 G93A 16 (10m; 6f) Vehicle 60 75/95
Group 7 Wild type 12 (6m; 6f) Vehicle 60 75/95
biOcheMical sTUDies
Group 8 SOD1 G93A 10 (5m; 5f) Bexarotene 60 95
Group 9 SOD1 G93A 10 (5m; 5f) Vehicle 60 95
Group 10 Wild type 10 (5m; 5f) Vehicle 60 95
and immunofluorescence. The early loss of MN was evaluated at 
day 75 and 95 of life. The number of MNs was counted in four 
sections of each animal at segment L4 using hematoxylin–eosin 
staining. Only polygonal-shaped neurons present in ventral horns, 
larger than 20 μm and with prominent nucleoli, were used for the 
quantitative analysis as previously reported (Mancuso et al., 2014).
For immunofluorescence, tissue sections and squash prepara-
tions were sequentially treated with 0.5% Triton X-100 in PBS, 
0.1M glycine in PBS containing 1% bovine serum albumin and 
incubated with the primary antibody overnight at 4°C. Then, the 
sections were incubated with the specific secondary antibody 
conjugated with FITC or Cy3 and mounted with Vectashield 
(Vector, USA). Confocal images were obtained with a LSM510 
(Zeiss, Germany) laser scanning microscope using 40× oil or 
63× oil (1.4 NA) objectives. In order to avoid overlapping signals, 
images were obtained by sequential excitation at 488 and 543 nm, 
to detect FITC and Cy3, respectively. Images were processed using 
Photoshop software.
To quantify astrogliosis, confocal images of the ventral horn’s 
gray matter immunostained for glial fibrillary acidic protein 
(GFAP) were recorded by using a 40× oil objective and the same 
confocal settings. Images were background corrected by refer-
ence regions outside the tissue and fluorescence intensities were 
estimated by using the ImageJ software (NIH, Bethesda, MD, USA; 
http://rsb.info.nih.gov/ij/).
The relative nuclear levels of RXRα in MNs of wild type, 
Bxt-treated and vehicle-treated transgenic SOD1G93A mice were 
determined on 5 μm thick cryostat sections immunostained with 
the anti-RXRα antibody. Only anterior horn neurons larger than 
20 μm and with prominent nucleoli were sampled. We used three 
animals per experimental group and at least 35 neurons per animal 
were sampled. Confocal images were recorded by using a 63× oil 
objective (NA 1.4) and the same confocal settings at a resolution 
of 1024  ×  1024  pixels. The same immunostaining and image 
processing procedures were carried out for all the experimental 
groups. Images were background corrected by reference regions 
outside the tissue and fluorescence intensities of nuclear RXRα 
signal, excluding the nucleolus, were estimated by using the ImageJ 
software (NIH, Bethesda, MD, USA; http://rsb.info.nih.gov/ij/).
The following primary antibodies were used: goat polyclonal 
 antibodies anti-choline acetyltransferase (ChAT) (Millipore, 
Billerica, MA, USA) and anti-cathepsin D (Santa Cruz Biotechnology, 
USA), and rabbit polyclonal antibodies anti-GFAP (Dako, 
Glostrup, Denmark), anti-SOD1 (Enzo Life Sciences, Switzerland), 
anti-ubiquitin-protein conjugates (Santa Cruz Biotechnology, 
USA), and anti-RXRα (D-20, Santa Cruz Biotechnology, USA).
electron Microscopy
For electron microscopy, transgenic mice were perfused with 1% 
glutaraldehyde and 1% paraformaldehyde in 0.12M phosphate 
buffer. Tissue samples of the anterior horn were dehydrated and 
embedded in Araldite. Ultrathin sections were examined with a 
Jeol 201 electron microscope.
To determine the ultrastructural localization of cathepsin D in 
lysosomes, we performed immunogold electron microscopy. Tissue 
samples of the anterior horn fixed with 3.7% paraformaldehyde 
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were dehydrated in methanol and embedded in Lowicryl K4M 
at −20°C. Ultrathin sections were sequentially incubated with 
0.1M glycine in PBS (15 min), 5% BSA in PBS (30 min), and the 
anti-cathepsin D antibody diluted in PBS containing 0.1M glycine 
and 1% BSA (1 h at room temperature). After washing, the sections 
were incubated with an anti-goat secondary antibody conjugated 
to 10 nm gold-particles (BioCell, UK) diluted 1:25 in 1% BSA in 
PBS (45 min at room temperature). After washing, the sections 
were stained with uranyl acetate and lead citrate. Control sections 
were treated as described but omitting the primary antibody.
Western blotting and real Time Quantitative 
Pcr
Ten transgenic mice, treated with Bxt or vehicle from day 60 until 
day 95 of life, were used in these studies. For each biochemical assay 
(rtqPCR or WB) at least three mice of each animal group were 
used. Age-matched wild type mice receiving vehicle were used 
for comparison. After being anesthetized, they were decapitated 
and the lumbar spinal cord quickly removed and frozen in liquid 
nitrogen.
Gene expression was assessed by rtqPCR. RNA from spinal 
cord samples was isolated with Trizol following the manufacturer’s 
instructions (Invitrogen, Carlsbad) and purified with the RNeasy 
kit (Qiagen, Hilden, Germany) as previously reported (Delgado-
Calle et al., 2011). Aliquots of RNA were reverse-transcribed with 
the PrimeScrip RT kit (Takara) using random hexamers as primers. 
Then, the expression of cathepsin D was determined rtqPCR using 
gene-specific primers and TaqMan probes (Life Technologies, 
Foster City, CA, USA). The threshold cycle (Ct) for each well 
was determined. The results were normalized to hypoxanthine 
phosphoribosyltransferase 1 (HPRT1). Relative gene expression 
was calculated as 2−ΛCT, where ΛCT is the difference between the 
gene of interest threshold cycle and the HPRT1 threshold cycle.
For WB analysis, the spinal cord samples (the ventral region 
of lumbosacral enlargement) were homogenized in a lysis buffer 
(100 mM NaCl, 10 mM Tris-HCl, pH 7.5, 1 mM EDTA, and 1 μg/
ml aprotinin) and the homogenates were centrifuged. The protein 
in the supernatants were subjected to SDS-PAGE electrophoresis 
and afterwards transferred to polyvinylidene difluoride mem-
branes, stained with antibodies, and visualized with the Odyssey 
system (LI-COR Biotechnology). Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) and tubulin were used as protein loading 
controls. The antibodies used were a goat polyclonal anti-cathepsin 
D (Santa Cruz Biotechnology, Europe) and mouse monoclonal 
anti-GAPDH (Abcam, Cambridge, MA, USA). ImageJ software 
(U. S. National Institutes of Health, Bethesda, MD, USA) was used 
to quantify the density and size of the blots.
statistical analysis
The significance of the differences in weight was tested by 
unpaired Student’s t-test, while non-parametric Mann–Whitney 
U test was used to compare motor test scores of the Bxt- and 
vehicle-treated groups. The overall survival and time-course of 
motor deterioration plots were obtained with the Kaplan–Meier 
procedure, followed by between-group curve comparisons with 
the Gehan–Breslow–Wilcoxon test.
The number of MNs in the anterior horn was tested with 
ANOVA test. Intracellular ubiquitin aggregates, the relative 
nuclear levels of RXRα, and both the integrated GFAP and RXRα 
signal assessing astrogliosis were also tested with ANOVA test. 
The significance of differences of WB and rtqPCR was analyzed 
with non-parametric Kruskal–Wallis test. p-Values <0.05 were 
considered as significant. All analyses were two-tailed.
results
bxt Treatment Delays Weight loss and extends 
survival in sOD1g93a Mice
Bxt was well tolerated with no obvious signs of toxicity or drug-
related deaths; in fact, the general condition was better preserved 
in the transgenic mice treated with Bxt than in vehicle-treated 
transgenic mice. Animals that received vehicle started to lose 
weight at day 80, while those receiving Bxt continued gaining 
weight until day 110. Bxt-treated mice weighed up to 20% more 
than controls. Differences in weight were significant from day 
90 onward (Figure 1A). In comparison with wild type mice, the 
weight of transgenic mice was 75 and 89% in the vehicle-treated 
and Bxt-treated groups, respectively. Bxt-treated transgenic 
animals remained more physically active than controls receiving 
vehicle. However, Bxt administration to wild type mice induced no 
significant changes in either body weight or neuromuscular tests.
Bxt treatment also prolonged the survival of SOD1G93A trans-
genic mice. The first death occurred on day 117 in the control group 
and on day 125 in the Bxt group. The median survival was 10 days 
longer in the group of animals treated with Bxt [139 vs. 129 days; 
Gehan–Breslow–Wilcoxon test, p = 0.03; hazard ratio = 0.29, 95% 
confidence intervals (CI): 0.11–0.80] (Figure 1B).
bxt Preserves the neuromuscular Function 
Delaying the Disease Onset in sOD1g93a Mice
Disease onset assessed by neuromuscular tests was also signifi-
cantly delayed in Bxt-treated mice. Wild type mice and transgenic 
mice prior to disease onset were consistently able to stand for more 
than 1500 s on the Rotarod spinning wheels. The Rotarod median 
performance in the vehicle-treated transgenic mice started to 
decrease on day 96, while in the Bxt-treated animals did not change 
till day 113 (Figure 2A). The median time to reach a threshold of 
marked deterioration (established at 150 s in the present study) 
was 110 days in the vehicle-treated group and 119 days in the Bxt-
treated group (Gehan–Breslow–Wilcoxon test, p = 0.033; hazard 
ratio = 0.42; 95% CI: 0.16–1.07) (Figure 2B). Similarly, wild type 
mice and presymptomatic transgenic mice were consistently able 
to hang for more than 600 s. Deterioration of the four-limb hang-
ing test scores appeared to begin in both transgenic mice groups 
approximately on day 100. However, vehicle-treated mice showed 
more rapid deterioration than Bxt-treated animals. From day 110 
to day 124, Bxt-treated animals were able to cling for twice as much 
time in comparison to those receiving vehicle (p-values 0.03–0.05). 
Significant between-group differences also existed regarding the 
time to reach stages of moderate or advanced deterioration. Thus, 
the median age to hang <50 s was 112 days in vehicle-treated mice 
and 120 days in the Bxt-treated group (Gehan–Breslow–Wilcoxon 
FigUre 2 | bexarotene treatment enhances motor performance in sOD1g93a mice. Bexarotene treatment (Bxt) delays neuromuscular function deterioration 
as assessed by Rotarod (a,b) and hanging (c) tests.
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test, p = 0.01; hazard ratio = 0.36; 95% CI: 0.13–0.96) (Figure 2C). 
Similarly, significant between-group differences existed when a 
10-s score was considered (p = 0.006).
bxt Partially Preserves Mn cytology and 
ameliorates the spinal Mn loss in  
sOD1g93a Mice
As expected, the ongoing expression of the mutant transgene 
induced the development of neuromuscular changes in both 
groups of transgenic mice. However, our results showed that 
chronic administration of Bxt delayed the appearance of clinical 
manifestations of the disease. Therefore, we decided to explore 
whether the drug also delay histological alterations at presymp-
tomatic stages. At day 75, marked abnormalities were observed 
in transgenic mice receiving vehicle, by contrast no gross abnor-
malities were observed in their behavior or motor performance. 
By conventional hematoxylin–eosin staining, the anterior horn 
of control wild type mice showed the typical organization of 
MNs with prominent nucleoli and Nissl bodies in addition to a 
compact neuropile (Figures 3A,D). Conversely, degenerative signs 
were observed in the anterior horn of vehicle-treated SOD1G93A 
mice. They consisted of cytoplasmic vacuolization of some MNs 
and spongiform changes of the neuropile (Figures 3B,E). These 
alterations were much less pronounced in transgenic mice treated 
with Bxt, where both MNs and neuropile generally appeared well 
preserved (Figures 3C,F).
FigUre 1 | effects of bexarotene on weight and survival. (a) Bexarotene treatment (Bxt) delays the start-up of weight loss as compared with the vehicle-
treated (Vhc) transgenic SOD1G93A mice. (b) Survival analysis showing increase of lifespan in the Bxt group as compared with the Vhc group. WT, wild type mice.
We next analyzed the MN loss at both presymptomatic and 
early-symptomatic stages. This was assessed by evaluating the 
number of MN cell bodies in cryosections of the anterior horn 
(segments L4 and L5) stained with PI that fulfilled the previously 
referred criteria (Mancuso et al., 2014). On day 75, vehicle-treated 
SOD1G93A mice had 13.5 ± 0.23 MNs per section, while Bxt-treated 
SOD1 mice had 16.4 ± 0.25 MNs per section (74 and 90%, respec-
tively, of MNs in wild type mice) (Figure 3G). The differences 
were more marked, at day 95 of life, when in the vehicle-treated 
group there were 8.6 ± 0.3 MNs per section, whereas 12.9 ± 0.30 
MNs were present in Bxt-treated mice (48 and 72%, respectively, 
of MNs in wild type mice). Differences were significant at both 
stages (p < 0.001) (Figure 3G).
The morphological changes observed by conventional hema-
toxylin–eosin staining were further characterized by PI staining 
and ultrastructural analysis. On day 75, fluorescent staining 
of nucleic acid with PI revealed prominent nucleoli and Nissl 
bodies in healthy wild type MNs (Figures 4A,D) and different 
levels of chromatolysis in MNs of the vehicle-treated transgenic 
SOD1G93A mice (Figures  4B,E,F). Large cytoplasmic vacuoles 
unstained with PI were commonly observed in advanced stages 
of MN degeneration (Figure 4F). In contrast, most MNs in Bxt-
treated SOD1G93A mice exhibited well-preserved Nissl bodies and 
prominent nucleoli (Figures 4C,G). Electron microscopy analysis 
on day 75 confirmed that the preservation of the basic cellular 
organization in MNs of Bxt-treated SOD1G93A mice. This included 
the normal structure of the nucleolus and chromatin as well as the 
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cytoplasmic domains enriched in rough endoplasmic reticulum 
(RER) and free polyribosomes (Figure 4H). In contrast, a severe 
disruption of RER (chromatolysis), associated with the presence 
of abnormal and swelling mitochondria and different degrees of 
vacuolar degeneration, was frequently observed in MNs of the 
vehicle-treated SOD1G93A mice (Figures 4I–J).
The pathogenic basis of the transgenic SOD1G93A mouse model 
lies on the over-expression of the toxic SOD1G93A protein (Jaarsma 
et al., 2000; Sau et al., 2007; Brotherton et al., 2012). To confirm 
the validity of the experimental model, we decided to investigate 
if chronic administration of Bxt modulated the expression of the 
transgene. Interestingly, rtqPCR analysis revealed no significant 
differences in human SOD1 mRNA levels between Bxt-treated 
and vehicle-treated transgenic mice (Figure 4N). Additionally, 
we also assessed the mutant SOD1 protein distribution by 
immunofluorescence. While MNs from wild type mice showed 
a weak diffuse staining of the endogenous SOD1 (Figure 4K), 
a strong fluorescent signal corresponding to the mutant SOD1 
was clearly detected in the cytoplasm of MNs from SOD1G93A 
mice. Moreover, SOD1 immunoreactivity was absent from the 
nucleus (Figures  4L,M). At day 75, accumulations of mutant 
SOD1 were commonly observed throughout the cytoplasm, 
FigUre 3 | light microscopy findings in the anterior horn. (a–c) 
Representative examples of anterior horn cross sections stained with 
hematoxylin–eosin from 75 day-old wild type [WT (a)] mice and vehicle-
treated [Tg-Vhc (b)] and Bxt-treated [Tg-Bxt (c)] transgenic SOD1 G93A  
mice. The gray matter in the WT mouse shows the typical organization  
of MNs and a compact neuropile. Note that while MNs appear well 
preserved in the Tg-Bxt image, the Tg-Vhc image exhibits a reduced number 
of MNs and a spongiform alteration of the neuropile. Scale bar: 50 μm. 
(D–F) Higher magnification images illustrate the prominent vacuolar 
degeneration of MNs in the Tg-Vhc transgenic mice. Scale bar: 25 μm.  
(F) Quantitative analyses of spinal cord MNs at 75 and 95 days of age  
(g) (***p < 0.001).
excluding vacuoles, in degenerating MNs from vehicle-treated 
transgenic mice (Figure  4L). However, a lower cytoplasmic 
concentration of this mutant protein, visible as a diffuse staining 
and small aggregates, was found in MNs of Bxt-treated mice 
(Figure 4M). These findings suggest that Bxt partially prevents 
mutant protein aggregation and preserves neuronal proteostasis 
until more advanced stages.
The histological analysis of the anterior horn at symptomatic 
stages of disease (95 days old) shows morphological alterations in 
both groups of transgenic SOD1G93A mice. Thus, light microscopy 
analysis of toluidine blue stained semithin sections clearly dem-
onstrated the presence of degenerating MNs (Figures 5A,B). 
However, whereas most MNs exhibited severe vacuolar 
degeneration in vehicle-treated mice (Figure 5A), some well-
preserved MNs coexisted with others that displayed different 
levels of vacuolar degeneration in Bxt-treated mice (Figure 5B). 
In both transgenic groups of animals, the ultrastructural analy-
sis of MNs in advanced stages of neurodegeneration revealed 
(i) mitochondrial alterations, including dilation of cristae, 
presence of dense granules in the matrix, and global swelling 
resulting in the formation of large vacuoles, (ii) disruption 
of the RER, (iii) presence of lipid droplets, (iv) proliferation 
FigUre 4 | Morphological alterations of Mns. Representative examples of 
anterior horn cross cryosections stained with PI from 75 days old wild type [WT 
(a)] mice and vehicle-treated [Tg-Vhc (b)] and Bxt-treated [Tg-Bxt (c)] transgenic 
SOD1G93A mice. Note that the prominent nucleoli in all MNs and the well-
preserved Nissl bodies in both WT and Tg-Bxt animals. Several MNs in the 
anterior horn of the Tg-Vhc mouse exhibit a severe cytoplasmic disruption with 
vacuolar degeneration and chromatolysis (white arrows). Scale bar: 20 μm. (D–g) 
Higher magnification images of dissociated MNs stained with PI from WT (D), 
Tg-Vhc (e–F), and Tg-Bxt mice (g). Note that the typical distribution of Nissl 
bodies in the WT MN (D) and different stages of chromatolysis and vacuolar 
degeneration in MNs from the Tg-Vhc mouse (e,F). Scale bar: 7.5 μm. (h–J) 
Electron micrographs of MNs from Tg-Bxt (h) and Tg-Vhc transgenic SOD1G93A 
mice (i,J). The MN from the Tg-Bxt mouse exhibits a well preserved nuclear and 
cytoplasmic structure, including typical arrays of RER cisterns (asterisks). MNs 
from the Tg-Vhc mice show severe chromatolysis (asterisks), extensive 
cytoplasmic vesiculation, mitochondrial abnormalities (m), and accumulation of 
large vacuoles derived from altered mitochondria (m). Scale bars: (h), 4 μm; (i,J), 
3 μm. (K–M) Representative confocal microscopy images of MNs immunolabeled 
for SOD1 from the WT (K) and Tg-Vhc (l) and Tg-Bxt (M) SOD1G93A mice. Strong 
immunostaining signal of SOD1 appears throughout the cytoplasm, excluding the 
lumen of large vacuoles, in the MN of the Tg-Vhc mouse. Scale bar: 5 μm. (n) 
Transgene expression in Bxt-treated and Vhc-treated transgenic mice.
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excluding vacuoles, in degenerating MNs from vehicle-treated 
transgenic mice (Figure  4L). However, a lower cytoplasmic 
concentration of this mutant protein, visible as a diffuse staining 
and small aggregates, was found in MNs of Bxt-treated mice 
(Figure 4M). These findings suggest that Bxt partially prevents 
mutant protein aggregation and preserves neuronal proteostasis 
until more advanced stages.
The histological analysis of the anterior horn at symptomatic 
stages of disease (95 days old) shows morphological alterations in 
both groups of transgenic SOD1G93A mice. Thus, light microscopy 
analysis of toluidine blue stained semithin sections clearly dem-
onstrated the presence of degenerating MNs (Figures 5A,B). 
However, whereas most MNs exhibited severe vacuolar 
degeneration in vehicle-treated mice (Figure 5A), some well-
preserved MNs coexisted with others that displayed different 
levels of vacuolar degeneration in Bxt-treated mice (Figure 5B). 
In both transgenic groups of animals, the ultrastructural analy-
sis of MNs in advanced stages of neurodegeneration revealed 
(i) mitochondrial alterations, including dilation of cristae, 
presence of dense granules in the matrix, and global swelling 
resulting in the formation of large vacuoles, (ii) disruption 
of the RER, (iii) presence of lipid droplets, (iv) proliferation 
FigUre 4 | Morphological alterations of Mns. Representative examples of 
anterior horn cross cryosections stained with PI from 75 days old wild type [WT 
(a)] mice and vehicle-treated [Tg-Vhc (b)] and Bxt-treated [Tg-Bxt (c)] transgenic 
SOD1G93A mice. Note that the prominent nucleoli in all MNs and the well-
preserved Nissl bodies in both WT and Tg-Bxt animals. Several MNs in the 
anterior horn of the Tg-Vhc mouse exhibit a severe cytoplasmic disruption with 
vacuolar degeneration and chromatolysis (white arrows). Scale bar: 20 μm. (D–g) 
Higher magnification images of dissociated MNs stained with PI from WT (D), 
Tg-Vhc (e–F), and Tg-Bxt mice (g). Note that the typical distribution of Nissl 
bodies in the WT MN (D) and different stages of chromatolysis and vacuolar 
degeneration in MNs from the Tg-Vhc mouse (e,F). Scale bar: 7.5 μm. (h–J) 
Electron micrographs of MNs from Tg-Bxt (h) and Tg-Vhc transgenic SOD1G93A 
mice (i,J). The MN from the Tg-Bxt mouse exhibits a well preserved nuclear and 
cytoplasmic structure, including typical arrays of RER cisterns (asterisks). MNs 
from the Tg-Vhc mice show severe chromatolysis (asterisks), extensive 
cytoplasmic vesiculation, mitochondrial abnormalities (m), and accumulation of 
large vacuoles derived from altered mitochondria (m). Scale bars: (h), 4 μm; (i,J), 
3 μm. (K–M) Representative confocal microscopy images of MNs immunolabeled 
for SOD1 from the WT (K) and Tg-Vhc (l) and Tg-Bxt (M) SOD1G93A mice. Strong 
immunostaining signal of SOD1 appears throughout the cytoplasm, excluding the 
lumen of large vacuoles, in the MN of the Tg-Vhc mouse. Scale bar: 5 μm. (n) 
Transgene expression in Bxt-treated and Vhc-treated transgenic mice.
FigUre 5 | Morphological alterations of Mns at symptomatic stages 
of neurodegeneration. (a,b) Toluidine blue staining of gray matter sections 
from vehicle-treated [Tg-Vhc (a)] and Bxt-treated [Tg-Bxt (b)] transgenic 
SOD1G93A mice at day 95. The (a) shows MN loss and prominent vacuolar 
degeneration of remnant cell bodies. The (b) illustrates well-preserved 
neuronal bodies (arrows) coexisting with other ones exhibiting different levels 
of vacuolar degeneration. Scale bar: 20 μm. (c–e) Representative electron 
micrographs of MNs from Tg-Vhc (c,D) and Tg-Bxt (e) mice at advanced 
stages of neurodegeneration. (c,D) The cell bodies show large vacuoles 
containing remnants of degenerated mitochondria (m), with dilatation of the 
intermembranous space (asterisk) and presence of dense granules (arrows), 
in addition to cytoplasmic accumulation of small vesicles and nuclear 
eccentricity. The inset illustrates a typical axonal vacuolar degeneration of a 
myelinated fiber (Ax). (e) Detail of cytoplasm from a Bxt-treated MN 
illustrating the initial dilation of mitochondrial cristae. Scale bars: (c–e) 3 μm, 
inset 2.6 μm.
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of neurofilaments, and (v) frequently nuclear eccentricity 
(Figures 5C–E). Moreover, axonal degeneration of myelinated 
fibers was a common finding in the neuropile at symptomatic 
stages (Figure 5D, inset). As expected, histological analysis of 
animals euthanized at the full paralysis stage showed similar 
abnormalities in both groups.
bxt induces nucleolar hypertrophy in spinal 
cord Mns of sOD1g93a Mice
It is well established that the nucleolus plays an essential role in 
the synthesis of rRNAs and molecular assembly of pre-ribosomal 
particles (Raska et al., 2006; Boisvert et al., 2007). Indeed, the 
nucleolar configuration and size correlated with the transcrip-
tional activity of the ribosomal genes in mammalian neurons 
(Kinderman and Jones, 1993; Berciano et al., 2007; Hetman and 
Pietrzak, 2012; Palanca et al., 2014). To determine the possible 
contribution of the nucleolus to the neuroprotective effects of 
Bxt, we have analyzed the structural organization and size of MN 
nucleoli. Squash preparations of MNs stained with PI revealed the 
euchromatic nuclear configuration and the presence of prominent 
nucleoli with a high intensity of rRNA signal in wild type mice as 
well as in both vehicle-treated and Bxt-treated transgenic mice 
(Figures 6A–C). Morphometric analysis of nucleolar diameter 
on presymptomatic day 60 (before starting Bxt treatment) did 
not reveal significant differences between wild type and trans-
genic SOD1G93A mice. However, at an early-symptomatic stage 
(95 days old), the nucleolar diameter of MNs was significantly 
higher in MNs of SOD1G93A mice treated with Bxt for 30 days 
than those in MNs of both wild type and vehicle-treated SOD1G93A 
mice (Figure  6F). Electron microscopy analysis confirmed 
this nucleolar hypertrophy, and also revealed the reticulated 
nucleolar configuration, with numerous fibrillar centers, in 
most of MNs of both vehicle-treated and Bxt-treated SOD1G93A 
mice (Figures 6D,E). The Bxt-induced increase in nucleolar size 
is consistent with a neuroprotectetive response of the nucleolus 
for enhancing ribosome biogenesis.
FigUre 6 | nucleolar response of Mns in transgenic sOD1G93A mice. 
Higher magnification images of dissociated MNs stained with PI from wild type 
[WT (a)], vehicle-treated [Tg-Vhc (b)], and Bxt-treated [Tg-Bxt (c)] mice at day 
95. MNs from Bxt-treated mice have a larger nucleolus. Scale bar: 5 μm. (D,e) 
Representative electron micrographs of MN nucleoli from [Tg-Vhc (D)] and 
[Tg-Bxt (e)] illustrating their reticulated configuration (hch: heterochromatin 
mass). Scale bar (D,e): 1 μm. (F) Morphometric analysis of nucleolar diameters 
of MNs at 60 and 95 days old (*p < 0.05).
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bxt contributes to Modulate cellular 
Proteostasis in the spinal cord Mns of  
sOD1g93a Mice
Protein aggregation is a common feature of many neurodegenera-
tive diseases (Ross and Poirier, 2004). The presence of ubiquitylated 
protein aggregates has been widely described in ALS mice, consist-
ent with a dysfunction of cellular proteostasis (Robberecht and 
Philips, 2013). This prompted us to investigate whether Bxt reduces 
protein aggregation into ubiquitylated cytoplasmic inclusions. 
Immunostaining of semithin sections of the anterior horn with 
an antibody that recognizes ubiquitin-protein conjugates revealed 
a high-nuclear concentration of ubiquitylated proteins, exclud-
ing the nucleolus, and a diffuse cytoplasmic signal in MNs from 
both wild type and transgenic SOD1G93A mice (Figures 7A–C). 
Ubiquitin-positive cytoplasmic inclusions were commonly found 
in MNs exhibiting different levels of vacuolar degeneration and 
chromatolysis in vehicle-treated SOD1G93A mice (Figures 7B,D,E). 
The quantitative analysis of the proportion of MNs containing 
ubiquitin-positive cytoplasmic inclusions (Figure 7F) showed a 
significant reduction in Bxt-treated SOD1G93A mice as compared 
with vehicle-treated mice (14% vs. 43%, p < 0.001). These find-
ings strongly support a Bxt-induced enhancement of proteostasis 
resulting in lower levels of protein aggregation.
Together with the UPS, the autophagy-lysosome pathway is the 
other major proteolytic system (Korac et al., 2013). To evaluate the 
lysosomal response in transgenic SOD1G93A mice, we investigated 
the expression pattern of the protease cathepsin D, as a molecular 
marker of lysosomes. Immunostaining for cathepsin D in squash 
preparations counterstained with PI revealed the abundance of 
cathepsin D-positive lysosomes interspersed between Nissl bodies 
in wild type MNs (Figure 7G). However, a notable greater accu-
mulation of lysosomes, particularly at the perinuclear cytoplasm, 
was clearly visible in vehicle-treated transgenic mice (Figure 7H). 
Interestingly, most MNs in Bxt-treated transgenic mice displayed 
a cathepsin D pattern similar to that observed in wild type mice 
(Figure 7I). Conventional electron microscopy analysis showed 
FigUre 7 | alterations of proteostasis in Mns: the UPs and lysosome 
pathway. (a–c) Representative confocal images of anterior horn semithin 
sections immunostained for ubiquitin-protein conjugate from wild type mice 
[WT (a)], vehicle-treated [Tg-Vhc (b)], and Bxt-treated [Tg-Bxt (c)] transgenic 
SOD1G93A mice. Note that the presence of ubiquitin-positive cytoplasmic 
inclusions (white arrows) in MNs from the Tg-Vhc mouse (b). Scale bar: 
25 μm. (D,e) Detail of MNs from Tg-Vhc mice immunostained for ubiquitin 
and counterstained with PI. The MN in (D) shows the presence of ubiquitin-
positive cytoplasmic inclusion (arrows) and small Nissl bodies. A prominent 
vacuolar degeneration and ubiquitin-positive inclusions (arrows) are observed 
in the MN of (e). Scale bar (D,e): 10 μm. (F) Quantitative analyses of the 
proportion of MNs containing ubiquitylated inclusions (****p < 0.0001; 
***p < 0.001). (g–i) Representative examples of dissociated MNs 
immunostained for cathepsin D and counterstained with PI from WT (g), 
Tg-Vhc (h), and Tg-Bxt SOD1G93A mice (i). The MN of the Tg-Vhc mouse 
shows greater accumulation of lysosomes (h) than those observed in both 
WT and Tg-Bxt (g,i). Scale bar (g–i): 5 μm. (J) Electron micrograph of the 
cytoplasm of a MN from Tg-Vhc mouse illustrating the accumulation of 
lysosomes. Scale bar: 750 nm. (K) Immunogold electron microscopy image 
illustrating the localization of the cathepsin D in the electron-dense lysosomal 
matrix. Scale bar: 500 nm. (l–n) Western blot and real time rtqPCR analysis 
of cathepsin D (*p < 0.05).
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the accumulation of lysosomes in MNs of vehicle-treated trans-
genic mice (Figure  7J). Their lysosomal nature was confirmed 
with immunogold electron microscopy for cathepsin D. Gold 
particles decorated the cathepsin D-rich electron-dense matrix 
while the lipid-rich electron-lucent areas were free of immunola-
beling (Figure 7K). Biochemical analyses with rtqPCR and WB 
demonstrated an increase in cathepsin D mRNA and protein levels 
in the anterior horn of vehicle-treated transgenic SOD1G93A mice 
as compared with both Bxt-treated SOD1G93A and wild type mice 
(Figures 7L–N).
bxt Treatment increases nuclear expression 
levels of rXrα in Mns
On the basis that Bxt is an agonist of nuclear RXR receptors, 
which are ligand-dependent transcription factors, we investigated 
whether the neuroprotective effect of Bxt treatment could be par-
tially mediated by an increase in the nuclear expression of RXRα 
in MNs. At day 75, confocal microscopy images of immunolabeled 
MNs revealed a weak diffuse nuclear pattern of RXRα expression, 
excluding the negative nucleolus, in wild type mice (Figure 8A). 
A similar pattern but with the presence of some microfoci of 
low RXRα immunoreactivity was found in MNs of transgenic 
SOD1G93A mice (Figure 8B). Interestingly, Bxt-treatment induced a 
remarkable increase in nuclear RXRα immunolabeling with a non-
homogeneous distribution. Thus, RXRα appeared concentrated 
in numerous microfoci with higher fluorescence intensities than 
those observed in vehicle-treated MNs. These bright microfoci 
stood out over the diffuse nuclear staining (Figure 8C). In addi-
tion to the negative nucleolus, several irregular areas with very 
low or no RXRα signal were observed throughout de nucleus 
(Figure 8C). The measurement of nuclear (excluding nucleolus) 
fluorescent intensity of RXRα on confocal images, using the ImageJ 
software, showed a significant increase of this nuclear receptor 
signal in Bxt-treated MNs as compared with both wild type and 
vehicle-treated transgenic SOD1G93A mice (Figure 8D).
To further characterize the nuclear compartmentalization 
of RXRα in Bxt-treated neurons, we performed double labeling 
experiments combining RXRα detection with PI, as a marker of the 
neuronal nucleolus (Palanca et al., 2014), demonstrating the absence 
of RXRα in this nuclear compartment (Figure 8E). Moreover, we 
performed co-immunostaining for RXRα and the TMG-cap of spli-
ceosomal small nuclear ribonucleoproteins (snRNPs), as a marker 
of nuclear speckles of splicing factors. These nuclear structures are 
DNA free nuclear domains involved in the storage and process-
ing of pre-mRNA splicing factors (Lamond and Spector, 2003). 
Interestingly, nuclear microfoci of RXRα appeared distributed in 
euchromatin regions and were conspicuously absent from the DNA 
free nuclear speckles immunolabeled with the anti-TMG-cap anti-
body (Figures 8F–H). However, RXRα microfoci were frequently 
observed at the periphery of nuclear speckles (Figure 8H).
bxt contributes to Preserve the Mn environment 
in spinal cord of sOD1g93a Mice
It is well accepted that astrocytes are involved in ALS pathogenesis 
in both human patients (Haidet-Phillips et al., 2011) and rodent 
models (Yamanaka et  al., 2008). To determine the potential 
neuroprotective effects of Bxt treatment on the reactive astro-
glial response to MN neurodegeneration, we performed GFAP 
immunostaining on semithin (2 μm thick) sections of the anterior 
horn. As illustrated in Figures 9A–E, reactive astrogliosis with 
hypertrophic astrocytes, which is a common feature of SOD1G93A 
mice (Hall et al., 1998), was less pronounced in the anterior horn 
of Bxt-treated mice. Thus, at day 75, the densitometric analysis 
of GFAP fluorescence intensity measured in the gray matter of 
vehicle-treated and Bxt-treated SOD1G93A mice increased by 3.5 
and 2.3 times, respectively, respect to wild type mice (p < 0.001, 
wt vs. both Tg-Vhc and Tg-Bxt; p < 0.001, Tg-Vhc vs. Tg-Bxt) 
(Figure 9F). These findings reflect a Bxt-induced down-regulation 
of the reactive astroglial response.
Another important point of the astroglial response is the 
reorganization of the perisynaptic glia that enwraps synapses, 
excluding the synaptic cleft, and modulates synaptic transmis-
sion (Reichenbach et  al., 2010). Cholinergic synaptic boutons 
on MN cell bodies and dendrites were immunolabeled with the 
anti-ChAT antibody. Double immunostaining for GFAP and ChAT 
revealed the well-preserved morphology of the ChAT-positive 
MNs and their synaptic boutons in Bxt-treated SOD1G93A mice 
(Figures 9B,C). In contrast, the vacuolar degeneration and the loss 
of ChAT-positive synapses were prominent features in MNs from 
vehicle-treated SOD1G93A mice (Figure 9A). By day 75, electron 
microscopy analysis of perisomatic synapses confirmed the well 
preserved structure of both synaptic boutons and perisynaptic glia 
in Bxt-treated mice (Figure  9H). Conversely, severe structural 
alterations, namely dilatation of the synaptic cleft, detachment of 
synapses, and severe disruption of the perisynaptic glia, were found 
in the majority of MNs of mice treated with vehicle (Figure 9G).
Discussion
Amyotrophic lateral sclerosis is one of the most disabling and 
ominous neurodegenerative diseases, being Riluzole, with a mod-
est effect on survival, the only drug that can be currently offered to 
patients. Therefore, there is a pressing need to find new therapies 
to cure or at least ameliorate the severe course of the disease. Our 
study was undertaken to contribute to the search of new drugs 
for ALS patients.
Our results indicate that Bxt has a beneficial effect in transgenic 
SOD1G93A mice. In particular, treatment with this retinoid agonist 
significantly delayed the disease onset and extended lifespan. As 
expected, Bxt did not prevent the development of the disease, since 
it did not block the expression of the mutant transgene. This fact 
increases the external viability of our findings. Overall, our results 
suggest that Bxt exerts a neuroprotective effect by interacting 
with multiple cellular pathways. The main target of Bxt, the RXR, 
appeared to be overexpressed in MN nuclei of mice treated with 
the drug, confirming its target enhancement in the spinal cord 
after oral administration.
Some of early cellular alterations reported here and in previous 
studies (Chiu et al., 1995; Bendotti et al., 2001; Pasinelli et al., 2004; 
Zang et al., 2005; Martin et al., 2007; Koval et al., 2013; Vinsant 
et al., 2013a,b) in MNs of the SOD1G93A mouse include vacuolar 
degeneration of cell bodies and neuronal processes, mitochondrial 
alterations, presence of intracellular protein aggregates, synapse 
FigUre 8 | nuclear expression of the rXrα in Mns. (a–c) 
Immunofluorescence for RXRα in MN nuclei from wild type [WT (a)], 
vehicle-treated [Tg-Vhc (b)], and Bxt-treated [Tg-Bxt (c)] transgenic SOD1G93A 
mice. (D) Densitometric analysis of nuclear fluorescence intensity of RXRα 
signal in MNs (p < 0.001). (e) Double labeling for RXRα and PI in a MN from 
Bxt-treated SOD1G93A mouse revealed the absence of RXRα signal in the 
nucleolus. (F–h) Co-immunostaining for RXRα and TMG-cap in a MN nucleus 
from Bxt-treated SOD1G93A mouse. Note that the distribution of RXRα microfoci 
in euchromatin domains and their absence within the nuclear speckles. 
Scale bars: 4 μm.
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disruption, progressive loss of MNs, and astrogliosis in the anterior 
horn. All these changes reveal a severe neuronal dysfunction 
preceding clinical manifestations. Our histological results are 
consistent with the notion that Bxt, although unable to block the 
main pathophysiological mechanism, since it did not modify the 
mutant transgene expression, delayed disease onset by preserving 
MN homeostasis until more advanced stages.
A main target of Bxt, the RXRα, appeared overexpressed in MN 
nuclei of mice treated with the drug, suggesting that the neuro-
protective effect of Bxt was partially mediated by the activation of 
the RA signaling pathway. A similar neuronal nuclear localization 
of RXRα has been previously reported after spinal cord contusion 
injury, suggesting that the participation of the RA signaling in the 
physiological response to CNS injury (Schrage et al., 2006). When 
activated, RXR are known to promote transcription of numerous 
target genes (Evans and Mangelsdorf, 2014). Our results show a 
significant increase in the nuclear expression of RXRα in MNs of 
Bxt-treated SOD1G93A mice in comparison with MNs of vehicle-
treated SOD1G93A mice, suggesting a Bxt-induced up-regulation of 
protein-coding target genes. In this vein, RXRα appears distributed 
throughout the extensive nuclear domains of euchromatin (active 
chromatin), which is a chromatin configuration characteristic of 
MNs (Riancho et al., 2014), but it is excluded from the nucleolus 
and DNA free nuclear speckles of splicing factors (Lamond 
and Spector, 2003). Moreover, the numerous nuclear microfoci 
of RXRα induced by Bxt treatment have an organization and 
spatial distribution similar to those of transcription factories 
identified in neurons using the in  situ transcription assay with 
5′-fluorouridine incorporation into nascent RNA (Casafont et al., 
2006). Interestingly, some of these RXRα microfoci appear in the 
periphery of nuclear speckles, where specific highly active genes 
have been shown to localize (Xing et al., 1993; Moen et al., 2004). 
Taken together, the extensive nuclear localization of RXRα in MNs 
of Bxt-treated SOD1G93A mice supports that this nuclear receptor 
is actively engaged in transcriptional activation of target genes 
and presumably in epigenetic changes via chromatin remodeling 
(Evans and Mangelsdorf, 2014). This interpretation is also consist-
ent with the recent RXR cistrome data indicating the existence 
FigUre 9 | reactive astrogliosis and synaptic alterations. (a–e) 
Representative confocal images of anterior horn sections coimmunolabeled for 
ChAT and GFAP from Vhc-treated [Tg-Vhc (a,D)] and Bxt-treated [Tg-Bxt 
(b,c,e)] transgenic SOD1G93A mice. Note that the prominent reactive 
astrogliosis and vacuolar degeneration of MNs (white arrows) in the Tg-Vhc 
mouse (a,D). Scale bar: (a,b,D,e), 30 μm; (c), 10 μm. (F) Densitometric 
analysis of fluorescence intensity of GFAP (***p < 0.001). (g,h) Electron 
micrographs of perisomatic synapses with their associated perisynaptic glia 
from Tg-Vhc (g) and Tg-Bxt (h) MNs. Note that the well preserved synaptic 
structure in the MN from the Tg-Bxt mouse (h) and the disruption of the 
synaptic cleft (arrow) and perisynaptic glia (asterisks) in the MN from the 
Tg-Vhc mouse (g). Scale bar: 1 μm.
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of many thousands of genomic binding sites for a single nuclear 
receptor affecting elaborate networks of genes (Tang et al., 2011). In 
fact, several reports have suggested that retinoids play a protective 
role in degenerative and acquired neurological diseases, such as 
Alzheimer or stroke (Sato et al., 2008; Crockett et al., 2011; Obulesu 
et al., 2011; Shimada et al., 2013).
Retinoids modulate the expression of hundreds of genes, 
including a large number of neuronal genes (Lane and Bailey, 
2005; Evans and Mangelsdorf, 2014). In the case of ALS, 
retinoid-regulated neuronal genes might impact on important 
cellular processes, such as the antioxidant response (SOD1), 
neuroinflammation and immune modulation (VEGF, IL2, p65 
subunit of NFkβ), cytoskeletal organization (neurofilament L, M, 
H proteins), ion transport (K+ channel Kir2.1, L-type and N-type 
Ca++ channels), intracelular signaling (phospholipase A2, CREB, 
PKA), and synaptic homeostasis (ChAT, vesicular ACh and GABA 
transporters, NMDA receptor NR1 and kainate receptor GluR6) 
(Lane and Bailey, 2005; Kolarcik and Bowser, 2012). Overall, these 
effects could be partially responsible of the neuroprotective effect 
of Bxt in the transgenic SOD1 mouse model of ALS. However, 
the precise mechanism of action of retinoids in ALS remains to 
be elucidated. Although in a preliminary study Crochemore et al. 
(2009) reported that chronic administration of all-trans RA had 
a negative effect in transgenic ALS mice by reducing lifespan, our 
results are consistent with several studies supporting the neuropro-
tective role of retinoids. First, the administration of a retinoid-free 
diet in rats induced a phenotype similar to ALS, indicating that a 
defect in retinoid signaling could promote MN disease (Corcoran 
et al., 2002). Second, gene expression profiling in both ALS animal 
models and sALS patients have demonstrated altered transcription 
of genes related to retinoid pathways (Malaspina et al., 2001; Jokic 
et al., 2007; Malaspina and Turkheimer, 2007). Third, it has also 
been reported that RA signaling facilitates axon outgrowth and 
nerve regeneration, whereas its disruption leads to MN degenera-
tion (Maden, 2007). Moreover, Kolarcik and Bowser (2012) have 
recently analyzed the expression of genes of the retinoid pathway 
in the spinal cord of ALS patients and found that different isoforms 
of RAR correlated with the survival of MNs. In line with this, the 
authors demonstrated that pre-treatment of primary MNs-enriched 
cultures with a pan-RAR or RARβ-specific agonist decreased MN 
cell death associated with oxidative stress, while a RARβ-specific 
antagonist enhanced cell death. On the basis that RXR can also act 
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as heterodimers with peroxisome proliferator-activated receptor 
(PPAR) and liver X receptor (LXR), future experimental studies 
combining treatments with PPAR/LXR agonists and Bxt could be 
considered. This combined therapy might potentially enhance the 
neuroprotective effect of Bxt on MN survival.
As in other neurodegenerative diseases, oxidative and ER 
stresses with disturbed proteostasis are considered relevant 
features in ALS (Rothstein, 2009; Parakh et al., 2013; An et al., 
2014). Consistent with a proteostasis dysfunction, we have 
observed lysosomal proliferation, with up-regulation of cathepsin 
D expression and increased cytoplasmic aggregation of aberrant 
proteins into ubiquitylated inclusions in MNs of the vehicle-treated 
SOD1G93A mice. Several studies correlate the disturbance of neu-
ronal proteostasis with an impairment in the UPS and secondary 
dysfunction of autophagy-lysosome pathway (Martinez-Vicente 
and Cuervo, 2007). Although this pathway constitutes a physi-
ological mechanism to degrade proteins that “escape” from UPS 
and is beneficial for cell welfare (Tan et al., 2014), dysfunction 
of lysosomal proteolysis can be extremely harmful for neuronal 
function and survival (Ghavami et al., 2014). Indeed, up-regulation 
of the neuronal lysosomal system with increased levels of capthesin 
D is a prominent finding in Alzheimer’s disease (Cataldo et al., 
1995; Adamec et al., 2000). Similarly, altered mRNA and protein 
levels of cathepsin D have been correlated with more severe MN 
degeneration in a transgenic mouse model of ALS (Wootz et al., 
2006). The up-regulation of the lysosomal system reported here, in 
the SOD1G93A mouse, may simply reflect a compensatory response 
of MNs to the accumulation of aberrant proteins. However, several 
studies support a potential direct role of cathepsin D as mediator 
of neurotoxicity and cell death through abnormal permeabilization 
of lysosome and enzyme leakage into cytoplasm (Adamec et al., 
2000; Boya and Kroemer, 2008).
As expected, when compared with wild type mice, our trans-
genic SOD1G93A mice showed protein aggregates, identified as 
ubiquitylated inclusions, which are a pathological hallmark of ALS 
(Ferraiuolo et al., 2011; Bendotti et al., 2012). There is previous 
evidence that over-expression of mutant SOD1 protein tends to 
collapse the UPS by inducing ER stress, resulting in secondary 
accumulation of misfolded proteins and a severe disturbance of 
neuronal proteostasis (Saxena et al., 2009). The higher cytoplasmic 
accumulation of ubiquitylated inclusions and lysosomes in MNs 
from the vehicle-treated SOD1G93A than in MNs from Bxt-treated 
SOD1G93A mice suggests that Bxt treatment reduces proteostasis 
dysfunction. Consistent with this potential neuroprotective effect 
of Bxt on neuronal proteostasis, Rajawat et al. (2011) have recently 
reported that RA promotes the autophagy-lysosome pathway by 
inducing the acidification and maturation of the autophagosome 
through a mechanism independent of the classic retinoid nuclear 
receptors. Moreover, a recent study indicates that the administra-
tion of RA has a neuroprotective effect under conditions of UPS 
inhibition (Cheng et  al., 2013). In line with this concept, our 
results suggest that MNs from Bxt-treated SOD1G93A mice could 
have a greater ability to control proteostasis, and particularly to 
clear aberrant proteins, than MNs from vehicle-treated SOD1G93A 
mice. Upon detection of a pathobiological signal, neurons com-
monly activate a neuroprotective compensatory response that, 
if detrimental conditions persist, precedes the activation of the 
neurodegeneration and cell death. In this context, our results 
support that Bxt treatment delays the intricate progression of 
neuroprotection to neurodegeneration in ALS spinal cord MNs.
Spinal cord MNs from both wild type and transgenic SOD1G93A 
mice had prominent nucleoli with a reticular configuration (Riancho 
et al., 2014; present results). The nucleolar hypertrophy detected 
in MNs of Bxt-treated transgenic SOD1G93A mice seems to reflect 
a reactive nucleolar response to enhance nucleolar transcription 
and ribosome biogenesis. It is well established that nucleolar size 
positively correlates with both cell size and the transcription rate 
of rDNA genes (Raska et al., 2006; Berciano et al., 2007; Palanca 
et al., 2014). Enlargement of nucleolar size with up-regulation of 
ribosomal (rRNA) gene expression has previously been reported 
in experimental models of neuronal injury, such as axotomy and 
treatment with proteasome inhibitors (Kinderman and Jones, 
1993; Palanca et al., 2014). Nucleolar enlargement also occurs in 
MNs of ALS patients with very rapid clinical course (Wakayama, 
1992). The higher nucleolar size of the MNs of Bxt-treated mice, as 
compared with those of vehicle-treated mice, suggests an enhanced 
Bxt-induced compensatory response of the nucleolus to the ER 
stress caused by the mutant SOD1 protein (Kikuchi et al., 2006; 
Saxena et al., 2009). This neuroprotective response could sustain 
ribosome biogenesis and translational activity in order to delay the 
disruption of the protein synthesis machinery (chromatolysis) in 
transgenic SOD1G93A mice.
A remarkable finding here is the Bxt-induced reduction of 
astrogliosis combined with better preservation of the perisynaptic 
glia in transgenic SOD1G93A mice. Both cellular events also support 
a neuroprotective response. Reactive astrogliosis with hypertrophy 
and hyperplasia of astrocytes is a well-known response to degen-
eration and neuron loss. In the case of ALS, astrogliosis has been 
reported in both patients and murine models of the disease (Hall 
et al., 1998; Fischer et al., 2004). The slowdown of the astrogliosis 
response in Bxt-treated mice is consistent with the minor neurode-
generative signs observed in MNs. The involvement of astrogliosis 
in ALS pathogenesis is also supported by a recent study showing 
that spinal cord astrocytes expressing ALS-linked mutant SOD1 
release cytotoxic factors to MNs (Nagai et al., 2007). Regarding 
the possible cellular effects of Bxt on astrocyte behavior, a previous 
study in an experimental model of astrocyte–neuron co-culture 
demonstrated that treatment with all-trans RA induced the dif-
ferentiation and attenuated the astrocyte proliferation (Wohl and 
Weiss, 1998). This finding suggests that retinoids can contribute 
to down-regulate the proliferation (hyperplasia) of astrocytes in 
the transgenic SOD1G93Amice.
Synaptic alterations and their associated excitotoxicity in MNs 
have been widely studied in ALS as pathogenic mechanisms 
(Van Den et al., 2006; Sunico et al., 2011; Casas et al., 2013). In 
addition to the ultrastructural alterations in synaptic boutons 
previously reported in the SOD1G93A mice (Sunico et al., 2011), 
our results show a severe disruption of the perisynaptic glia that 
surround perisomatic MN synapses. Perisynaptic glia plays an 
important role in maintaining synaptic homeostasis through 
different functions, such as neurotransmitter traffic regulation, 
energy recycle, and ion homeostasis (Belanger and Magistretti, 
2009; Reichenbach et  al., 2010). The current findings support 
that these regulatory mechanisms may be overwhelmed in the 
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SOD1G93A mice, contributing to disease progression. In this vein, 
preservation or delayed disruption of perisynaptic glia in Bxt-
treated SOD1G93A mice could also represent an untapped potential 
mechanism of neuroprotection.
Several authors have reported a variety of treatments in 
the SOD1G93A mouse model of ALS. In view of our results, Bxt 
seems to be slightly better than riluzole and similar to other 
promising drugs recently tested (Gurney et al., 1998; Mancuso 
et al., 2014). In the future, mixed approaches combining drugs 
with synergic therapeutic effects will be worthwhile. In our 
view, one advantage of Bxt is that is a drug currently used in 
the clinical practice, a fact that would definitely facilitate future 
therapeutic trials.
In conclusion, the results of the present study demonstrate 
that chronic treatment with Bxt delayed disease onset, preserved 
motor function and extended survival in transgenic SOD1G93A 
mice. Multiple mechanisms may be involved in this neuropro-
tective effect, including the activation of the RXR target genes. 
Bxt ameliorated the MN loss in the ALS mice by preserving the 
organization of the cellular structures directly involved in proteo-
stasis, such as the protein synthesis machinery and the lysosomes. 
The Bxt-induced amelioration of proteostasis disturbance was also 
supported by the decrease of ubiquitylated cytoplasmic inclusions 
and by the neuroprotective nucleolar response. Additionally, Bxt 
contributed to protect MN environment by reducing reactive 
astrogliosis and synaptic alterations. Although further studies are 
needed to fully elucidate the molecular mechanisms involved in 
neuroprotective effects of Bxt, this drug appears to be a promising 
neuroprotective therapy for ALS, especially for those cases related 
to SOD1 mutations.
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